Market Overview

Intersect ENT, Inc. (XENT), Community Health Systems, Inc. (CYH) & Heron Therapeutics, Inc. (HRTX) - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

Share:

NEW YORK, July 05, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. 

Intersect ENT, Inc. (NASDAQ:XENT)
Class Period: August 1, 2018 - May 6, 2019
Deadline: July 15, 2019
For more info:
www.bgandg.com/xent

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Community Health Systems, Inc. (NYSE: CYH)
Class Period: February 20, 2017 - February 27, 2018
Deadline: July 29, 2019
For more info:
www.bgandg.com/cyh

The complaint alleges throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Community Health had understated its contractual allowances; (2) Community Health had understated its provision for bad debts; (3) Community Health had overstated its net operating revenue; (4) Community Health had understated its net loss; and (5) as a result of the foregoing, defendants' positive statements about Community Health's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Heron Therapeutics, Inc. (NASDAQ:HRTX)
Class Period: October 31, 2018 - April 30, 2019
Deadline: August 5, 2019
For more info:
www.bgandg.com/hrtx

The complaint alleges throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Heron had failed to include adequate Chemistry, Manufacturing, and Controls ("CMC") and non-clinical information in its NDA for HTX-011; (2) the foregoing increased the likelihood that the FDA would not approve Heron's NDA for HTX-011; and (3) as a result, Heron's public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

BGG Logo.jpg

View Comments and Join the Discussion!
 
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com